Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
AbstractHuman immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and nearly 1.6 million patients succumb to HIV each year. Several factors, including cross-species transmission and error-prone replication have resulted in extraordinary genetic diversity of HIV groups. One of these groups, known as group M (main) contains nine subtypes (A-D, F-H and J-K) and causes ~95% of all HIV infections. Most reported data on susceptibility and resistance to anti-HIV therapies are from subtype B HIV infections, which are prevalent in developed countries but account for only ~12% of all global HIV infections, whereas non-B subtype HIV infections that account for ~88% of all HIV infections are prevalent primarily in low and middle-income countries. Although the treatments for subtype B infections are generally effective against non-B subtype infections, there are differences in response to therapies. Here, we review how polymorphisms, transmission efficiency of drug-resistant strains, and differences in genetic barrier for drug resistance can differentially alter the response to reverse transcriptase-targeting therapies in various subtypes. View Full-Text
Share & Cite This Article
Singh, K.; Flores, J.A.; Kirby, K.A.; Neogi, U.; Sonnerborg, A.; Hachiya, A.; Das, K.; Arnold, E.; McArthur, C.; Parniak, M.; Sarafianos, S.G. Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors. Viruses 2014, 6, 3535-3562.
Singh K, Flores JA, Kirby KA, Neogi U, Sonnerborg A, Hachiya A, Das K, Arnold E, McArthur C, Parniak M, Sarafianos SG. Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors. Viruses. 2014; 6(9):3535-3562.Chicago/Turabian Style
Singh, Kamalendra; Flores, Jacqueline A.; Kirby, Karen A.; Neogi, Ujjwal; Sonnerborg, Anders; Hachiya, Atsuko; Das, Kalyan; Arnold, Eddy; McArthur, Carole; Parniak, Michael; Sarafianos, Stefan G. 2014. "Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors." Viruses 6, no. 9: 3535-3562.